XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2021   83,944,119      
Beginning balance at Dec. 31, 2021 $ 38,754,321 $ 8,394 $ 149,027,802 $ (154,973) $ (110,126,902)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 532,409   532,409    
Net income (loss) (8,398,670)       (8,398,670)
Foreign currency translation adjustments (9,150)     (9,150)  
Ending balance (in shares) at Mar. 31, 2022   83,944,119      
Ending balance at Mar. 31, 2022 30,878,910 $ 8,394 149,560,211 (164,123) (118,525,572)
Beginning balance (in shares) at Dec. 31, 2021   83,944,119      
Beginning balance at Dec. 31, 2021 38,754,321 $ 8,394 149,027,802 (154,973) (110,126,902)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (7,984,672)        
Foreign currency translation adjustments (145,019)        
Ending balance (in shares) at Jun. 30, 2022   84,820,858      
Ending balance at Jun. 30, 2022 33,033,459 $ 8,482 151,436,543 (299,992) (118,111,574)
Beginning balance (in shares) at Mar. 31, 2022   83,944,119      
Beginning balance at Mar. 31, 2022 30,878,910 $ 8,394 149,560,211 (164,123) (118,525,572)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 537,521   537,521    
Issuance of common stock from the exercise of warrants (in shares)   751,040      
Issuance of common stock from the exercise of warrants 1,218,750 $ 75 1,218,675    
Stock options exercised (in shares)   125,699      
Stock options exercised 120,149 $ 13 120,136    
Net income (loss) 413,998       413,998
Foreign currency translation adjustments (135,869)     (135,869)  
Ending balance (in shares) at Jun. 30, 2022   84,820,858      
Ending balance at Jun. 30, 2022 33,033,459 $ 8,482 151,436,543 (299,992) (118,111,574)
Beginning balance (in shares) at Dec. 31, 2022   84,825,481      
Beginning balance at Dec. 31, 2022 11,112,110 $ 8,482 152,529,579 (351,311) (141,074,640)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 624,621   624,621    
Issuance of common stock from the exercise of warrants (in shares)   1,353,515      
Issuance of common stock from the exercise of warrants 1,299,375 $ 136 1,299,239    
Net income (loss) (8,042,501)       (8,042,501)
Foreign currency translation adjustments (22,005)     (22,005)  
Ending balance (in shares) at Mar. 31, 2023   86,178,996      
Ending balance at Mar. 31, 2023 4,971,600 $ 8,618 154,453,439 (373,316) (149,117,141)
Beginning balance (in shares) at Dec. 31, 2022   84,825,481      
Beginning balance at Dec. 31, 2022 11,112,110 $ 8,482 152,529,579 (351,311) (141,074,640)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (16,804,733)        
Foreign currency translation adjustments (53,156)        
Ending balance (in shares) at Jun. 30, 2023   86,633,588      
Ending balance at Jun. 30, 2023 (2,719,402) $ 8,663 155,555,775 (404,467) (157,879,373)
Beginning balance (in shares) at Mar. 31, 2023   86,178,996      
Beginning balance at Mar. 31, 2023 4,971,600 $ 8,618 154,453,439 (373,316) (149,117,141)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 650,186   650,186    
Issuance of common stock from the exercise of warrants (in shares)   454,592      
Issuance of common stock from the exercise of warrants 452,195 $ 45 452,150    
Net income (loss) (8,762,232)       (8,762,232)
Foreign currency translation adjustments (31,151)     (31,151)  
Ending balance (in shares) at Jun. 30, 2023   86,633,588      
Ending balance at Jun. 30, 2023 $ (2,719,402) $ 8,663 $ 155,555,775 $ (404,467) $ (157,879,373)